Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, BMO Capital Markets Analyst Says

Gilead Sciences (NASDAQ:GILD) had its target price hoisted by stock analysts at BMO Capital Markets from $135.00 to $150.00 in a note issued to investors on Monday,MarketScreener reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective points to a potential upside of 10.35% from the company’s current price.

Several other research analysts have also weighed in on GILD. Scotiabank started coverage on Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target on the stock. Sanford C. Bernstein set a $135.00 target price on shares of Gilead Sciences and gave the company an “outperform” rating in a research note on Monday, December 29th. Rothschild & Co Redburn boosted their target price on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. TD Cowen increased their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Finally, Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $134.12.

Gilead Sciences Trading Up 3.7%

Shares of NASDAQ:GILD opened at $135.93 on Monday. The company’s 50-day moving average price is $123.98 and its two-hundred day moving average price is $118.71. Gilead Sciences has a one year low of $92.26 and a one year high of $136.30. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock has a market capitalization of $168.65 billion, a PE ratio of 21.07, a price-to-earnings-growth ratio of 0.71 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the previous year, the business earned $2.02 earnings per share. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts forecast that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the chief financial officer owned 150,503 shares in the company, valued at approximately $18,709,027.93. This represents a 1.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $70,740,911.34. This represents a 1.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 141,757 shares of company stock worth $17,569,112 in the last ninety days. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after acquiring an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares in the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at $2,150,268,000. Invesco Ltd. increased its stake in shares of Gilead Sciences by 12.0% in the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after purchasing an additional 1,618,453 shares during the last quarter. Finally, Amundi raised its holdings in shares of Gilead Sciences by 18.2% during the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after buying an additional 1,614,355 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.